December 1, 2014

homepage

January 9, 2015

X-Chem Announces Collaboration with Janssen and Johnson & Johnson Innovation to Advance Novel Candidates to Treat Inflammatory Diseases

WALTHAM, Mass. – January 9, 2015 – X-Chem, Inc. (“X-Chem”), a privately held biotechnology company applying its cutting-edge drug discovery platform to the generation of novel small molecule therapeutics, today announced a multi-target collaboration with Janssen Biotech, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson. The collaboration, which is being facilitated […]

Continue Reading
January 9, 2015

X-Chem Promotes Diala Ezzeddine to Executive Vice President and Chief Business Officer

WALTHAM, Mass. – January 9, 2015 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced that Diala Ezzeddine, Ph.D., has been promoted to executive vice president and chief business officer, effective December 6, 2014.

Continue Reading
December 17, 2014

X-Chem Licenses Cardiovascular Drug Discovery Program to Bayer Pharma AG

WALTHAM, Mass. – December 17, 2014 – X-Chem, Inc., a privately held biotechnology company focused on applying its innovative drug discovery capabilities to the generation of novel small molecule therapeutics, today announced it has licensed a second drug discovery program to Bayer Pharma AG pursuant to the multi-target collaboration the companies established in July 2012.

Continue Reading